Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 2Phase 2 2Phase NA 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Venous Thrombosis 2Pulmonary Embolism 2Hemorrhage 2Venous Thromboembolism 1Thromboembolism 1Thrombocytopenia 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Dalteparin 2edoxaban 1apixaban 1Tinzaparin 1Rivaroxaban 1Heparin, Low-Molecular-Weight 1Fluorodeoxyglucose F18 1Enoxaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Venous Thrombosis × Dalteparin × Clear all
NCT04731558 2025-02-14

PREPOSTEROUS

Helsinki University Central Hospital

Phase 4 Recruiting
1,012 enrolled
Gastrointestinal

Hemorrhage, Liver Neoplasms, Pulmonary Embolism, Venous Thrombosis

NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡